Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

Jessica Wegener of Whitelaw turned a healthy endeavor for her family into a business. She now creates customizable elderberry ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... Spraying insulin up the nose — where brain tissue reaches outside the brain, making up the ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET ...

Share on Pinterest Ozempic (semaglutide) is a medication approved ... one-to-one coaching with a registered nurse, including a step-by-step educational curriculum to help support your weight ...